Of striking significance, we showed that myeloid FoxO1 depletion–mediated improvement of hepatic inflammation translated into a significant beneficial effect on NASH, culminating in the reduction in hepatic injury and fibrosis in myeloid FoxO1–deficient versus WT littermates on a NASH diet. Here, FOXO1 is linked to metabolic dysfunction-associated steatohepatitis.